Published in Cancer Res on March 15, 2005
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med (2013) 2.55
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer (2009) 2.48
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) (2013) 2.17
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res (2007) 2.12
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer (2011) 1.95
A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology (2007) 1.88
Ovarian cancer pathogenesis: a model in evolution. J Oncol (2009) 1.77
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol (2010) 1.61
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res (2006) 1.52
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.52
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol (2011) 1.50
WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res (2006) 1.39
Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol (2011) 1.36
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (2010) 1.36
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer (2012) 1.27
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol (2011) 1.24
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res (2008) 1.23
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer (2008) 1.21
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer (2011) 1.19
HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn (2009) 1.16
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev (2009) 1.16
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol (2011) 1.12
Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol (2009) 1.10
A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol (2008) 1.09
In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem (2014) 1.04
Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin Oncol (2014) 1.02
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw (2008) 0.98
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol (2013) 0.98
BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database (Oxford) (2015) 0.97
Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther (2013) 0.96
Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer (2009) 0.94
Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene (2014) 0.94
Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol (2011) 0.94
Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer (2012) 0.93
Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Hum Pathol (2012) 0.92
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res (2013) 0.91
Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One (2013) 0.90
HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci (2013) 0.90
Identification of quiescent, stem-like cells in the distal female reproductive tract. PLoS One (2012) 0.87
High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res (2012) 0.87
Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing. Anal Bioanal Chem (2015) 0.85
HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci (2013) 0.85
HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep (2014) 0.85
Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer (2014) 0.85
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci (2013) 0.84
Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer. Int J Mol Sci (2013) 0.84
Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev (2015) 0.84
A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila) (2014) 0.83
Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer. PLoS One (2015) 0.83
PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis (2012) 0.83
Transcriptional and post-translational regulation of the quiescence factor and putative tumor suppressor p150(Sal2). FASEB J (2011) 0.83
Current clinical application of serum biomarkers to detect ovarian cancer. Prz Menopauzalny (2015) 0.82
Serum Human Epididymis Protein 4 (HE4) in the Differential Diagnosis of Peritoneal Tuberculosis: A Report of Two Cases. Balkan Med J (2014) 0.82
Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium. J Ovarian Res (2014) 0.81
Establishment of novel in vitro mouse chief cell and SPEM cultures identifies MAL2 as a marker of metaplasia in the stomach. Am J Physiol Gastrointest Liver Physiol (2014) 0.81
M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients. J Ovarian Res (2015) 0.81
Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor. PLoS One (2012) 0.81
HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection. Oncol Lett (2012) 0.81
Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites. Radiol Oncol (2014) 0.81
The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. PLoS One (2012) 0.80
The diagnostic accuracy of HE4 in lung cancer: a meta-analysis. Dis Markers (2015) 0.80
IL-36γ Augments Host Defense and Immune Responses in Human Female Reproductive Tract Epithelial Cells. Front Microbiol (2016) 0.80
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. J Korean Med Sci (2015) 0.79
Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett (2013) 0.79
Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer Res (2015) 0.79
Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer. Medicine (Baltimore) (2015) 0.79
Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. Chin J Cancer Res (2015) 0.77
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. Biomed Res Int (2015) 0.77
Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer (2015) 0.77
The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer. Tumour Biol (2014) 0.77
Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients. J Ovarian Res (2014) 0.76
Expression and diagnostic value of HE4 in pancreatic adenocarcinoma. Int J Mol Sci (2015) 0.76
Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight (2016) 0.76
A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research. Front Oncol (2017) 0.75
Early inflammatory response in epithelial ovarian tumor cyst fluids. Cancer Med (2014) 0.75
Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status? Tumour Biol (2016) 0.75
Multianalyte assay systems in the differential diagnosis of ovarian cancer. Expert Opin Med Diagn (2012) 0.75
Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. Oncotarget (2017) 0.75
Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir. Gene Ther Mol Biol (2015) 0.75
Utility of Pelvic MRI and Tumor Markers HE4 and CA125 to Predict Depth of Myometrial Invasion and Cervical Involvement in Endometrial Cancer. J Family Reprod Health (2015) 0.75
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. J Ovarian Res (2016) 0.75
Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studies. Facts Views Vis Obgyn (2015) 0.75
The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer. Open Med (Wars) (2016) 0.75
Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. Oman Med J (2016) 0.75
HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases. J Ovarian Res (2014) 0.75
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia. Br J Cancer (2016) 0.75
High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers. Proteomes (2014) 0.75
Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. Oncol Lett (2016) 0.75
Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer. Int J Clin Exp Med (2015) 0.75
Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat Biomed Eng (2017) 0.75
Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. Virchows Arch (2017) 0.75
p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA (2002) 4.32
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. Int J Cancer (2014) 2.74
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.43
Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol (2008) 2.42
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A (2004) 2.41
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell (2002) 2.24
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res (2006) 2.20
Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol (2010) 2.16
Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res (2011) 2.14
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell (2009) 2.13
Lymphomas of the breast: primary and secondary involvement. Cancer (2002) 2.06
Trimodal spectroscopy for the detection and characterization of cervical precancers in vivo. Am J Obstet Gynecol (2002) 2.02
Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev (2002) 1.97
Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol (2004) 1.92
NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes. Cancer Res (2002) 1.88
Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol (2009) 1.87
Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst (2002) 1.85
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol (2007) 1.80
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol (2010) 1.80
A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer (2007) 1.76
Colonization of second-trimester placenta parenchyma. Am J Obstet Gynecol (2008) 1.76
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70
Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer (2009) 1.68
Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet (2004) 1.64
A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64
Disruption of neural progenitors along the ventricular and subventricular zones in periventricular heterotopia. Hum Mol Genet (2008) 1.62
Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol (2009) 1.62
Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol (2009) 1.62
HPV testing. Visible expectations and hidden realities. Am J Clin Pathol (2003) 1.59
Microbiologic and histologic characteristics of the extremely preterm infant's placenta predict white matter damage and later cerebral palsy. the ELGAN study. Pediatr Res (2010) 1.57
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res (2003) 1.56
Eosinophilic dysplasia of the cervix: a newly recognized variant of cervical squamous intraepithelial neoplasia. Am J Surg Pathol (2004) 1.54
Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A (2011) 1.53
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res (2003) 1.53
Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res (2006) 1.52
Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Hum Pathol (2005) 1.52
Selenium binding protein 1 in ovarian cancer. Int J Cancer (2006) 1.47
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol (2010) 1.46
Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. Am J Surg Pathol (2013) 1.42
Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One (2012) 1.42
Assessment of factors that affect the quality of performance and interpretation of sonography of adnexal masses. J Ultrasound Med (2008) 1.41
Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer (2008) 1.36
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol (2010) 1.32
Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res (2006) 1.29
Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control (2007) 1.27
Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol (2009) 1.27
Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol (2010) 1.26
Blood protein profiles of infants born before 28 weeks differ by pregnancy complication. Am J Obstet Gynecol (2011) 1.25
Spectroscopic diagnosis and imaging of invisible pre-cancer. Faraday Discuss (2004) 1.25
Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol (2008) 1.25
p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.24
STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) (2011) 1.23
Do-it-yourself (DIY) pathology. Nat Biotechnol (2008) 1.23
SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes Dev (2004) 1.23
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res (2008) 1.23
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 1.22
Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol (2006) 1.22
Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res (2008) 1.21
Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol (2003) 1.20
Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia (2006) 1.20
Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues. Gynecol Oncol (2005) 1.19
Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Res (2002) 1.19
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol (2013) 1.19
Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One (2012) 1.18
Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology (2010) 1.18
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res (2004) 1.18
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One (2011) 1.18
Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers (2004) 1.17
Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res (2008) 1.17
T-bet regulates metastasis rate in a murine model of primary prostate cancer. Cancer Res (2004) 1.14
Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther (2002) 1.13
Intake of folate and related nutrients in relation to risk of epithelial ovarian cancer. Am J Epidemiol (2006) 1.12
Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol (2010) 1.11
Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.11
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res (2002) 1.10
Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia (2009) 1.10
Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol (2004) 1.10
Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res (2006) 1.10
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res (2003) 1.09